Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: Finlabo SIM Spa
$10.00
Provider: Reuters Investment Profile
$20.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Regeneron Pharmaceuticals Inc And Bayer AG's Bayer HealthCare Initiate Phase 3 Trial Of EYLEA (aflibercept) Injection For Treatment Of Diabetic Macular Edema In Asia And Russia REGN


Tuesday, 19 Feb 2013 02:30am EST 

Regeneron Pharmaceuticals Inc and Bayer AG's Bayer HealthCare announced that they have initiated a new Phase 3 trial (named VIVID EAST-DME) to evaluate the efficacy and safety of EYLEA (aflibercept) Injection in the treatment of Diabetic Macular Edema (DME) in Russia, China, and other Asian countries. The companies are extending their global development program for EYLEA in DME after promising results in the global Phase 2 DME program. Bayer HealthCare and Regeneron are collaborating on the global development of EYLEA. Regeneron maintains exclusive rights to EYLEA in the United States. Bayer HealthCare licensed the exclusive marketing rights outside the United States, where the companies will share equally the profits from any future sales of EYLEA, except for Japan where Regeneron will receive a royalty on net sales. 

Company Quote

101.1
-2.05 -1.99%
8:55am EDT